Healthy
Conditions
Brief summary
Assessment of safety of HLX02 at different doses. Randomised, double-blind, parallel group Phase I study to compare PK profiles and to assess the safety and immunogenicity between HLX02 and Herceptin® (U.S. and German).
Interventions
DRUGHLX02
DRUGHerceptin
Sponsors
Shanghai Henlius Biotech
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provide the singed informed consent form (ICF) 2. Healthy Chinese male subjects (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure and pulse rate measurement, 12 lead ECG, and clinical laboratory tests) 3. Aged ≥18 and ≤45 years 4. Body mass index (BMI) ≥19 and ≤28 kg/m2 5. Weight ≥50 and ≤80 kg 6. Left ventricular ejection fraction (LVEF) falls within the normal range as measured by echocardiogram (ECHO) within 14 days prior to randomisation 7. Subjects must agree that they and their female spouse/partners will use reliable contraception (2 forms of birth control, one of which must be barrier method) or be of non-childbearing potential from the time of the administration of investigational product (IP) until the completion of the study 8. Do not smoke or smoke fewer than 5 cigarettes daily within three months prior to screening; do not drink or drink less than 14 units of alcohol within six months prior to screening (1 unit of alcohol = 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine)
Exclusion criteria
1. Any history of clinically serious diseases such as hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, oncologic, or allergic diseases 2. Clinically significant abnormalities in laboratory test results 3. Previous exposure to any monoclonal antibody or current use of any biologics 4. History of allergic or anaphylactic reactions including those occurred during any clinical study or those caused by any drug or any of its excipients 5. Use of prescription or non prescription drugs and dietary supplements, within 5 half-lives of the drug or supplement, or within 2 weeks prior to taking IP (whichever is longer). Herbal supplements must be discontinued 28 days prior to the IP 6. History of a blood donation within 3 months prior to the administration of IP 7. Have participated in any other clinical study within 3 months prior to the administration of IP 8. Have positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) antibodies 9. Have a history of drug abuse 10. Unlikely to comply with the protocol requirements, instructions, and study related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits or improbability of completing the whole clinical study, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the concentration-time curve from time zero to infinity (AUCinf) | 57 days |
Secondary
| Measure | Time frame |
|---|---|
| Maximum serum concentration (Cmax) | 57 days |
| Time to Cmax (Tmax) | 57 days |
| Adverse event frequencies | 57 days |
| Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast) | 57 days |
Countries
China
Outcome results
None listed